NO953473D0 - Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling - Google Patents

Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling

Info

Publication number
NO953473D0
NO953473D0 NO953473A NO953473A NO953473D0 NO 953473 D0 NO953473 D0 NO 953473D0 NO 953473 A NO953473 A NO 953473A NO 953473 A NO953473 A NO 953473A NO 953473 D0 NO953473 D0 NO 953473D0
Authority
NO
Norway
Prior art keywords
responders
treating hepatitis
interferon therapy
hepatitis
potentiating
Prior art date
Application number
NO953473A
Other languages
English (en)
Other versions
NO953473L (no
NO320877B1 (no
Inventor
Paul B Chretien
Milton Mutchnick
Original Assignee
Alpha 1 Biomedicals Inc
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/027,500 external-priority patent/US6001799A/en
Application filed by Alpha 1 Biomedicals Inc, Univ Wayne State filed Critical Alpha 1 Biomedicals Inc
Publication of NO953473L publication Critical patent/NO953473L/no
Publication of NO953473D0 publication Critical patent/NO953473D0/no
Publication of NO320877B1 publication Critical patent/NO320877B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
NO19953473A 1993-03-05 1995-09-04 Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment NO320877B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/027,500 US6001799A (en) 1991-09-13 1993-03-05 Method of treating hepatitis C in non-responders to interferon treatment
PCT/US1994/002320 WO1994020131A1 (en) 1993-03-05 1994-03-03 Method of treating hepatitis c in non-responders to interferon treatment

Publications (3)

Publication Number Publication Date
NO953473L NO953473L (no) 1995-09-04
NO953473D0 true NO953473D0 (no) 1995-09-04
NO320877B1 NO320877B1 (no) 2006-02-06

Family

ID=21838079

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19953473A NO320877B1 (no) 1993-03-05 1995-09-04 Anvendelse av en immun-potensierende dose av minst ett thymosin eller immunsystempotensierende thymosinfragment

Country Status (17)

Country Link
EP (1) EP0687181B1 (no)
JP (1) JPH06279309A (no)
KR (1) KR100306024B1 (no)
CN (1) CN1072961C (no)
AT (1) ATE204760T1 (no)
AU (1) AU683248B2 (no)
CA (1) CA2157479C (no)
DE (1) DE69428112T2 (no)
DK (1) DK0687181T3 (no)
ES (1) ES2162862T3 (no)
FI (1) FI954127A0 (no)
GR (1) GR3037021T3 (no)
MY (1) MY121198A (no)
NO (1) NO320877B1 (no)
PT (1) PT687181E (no)
SG (1) SG64894A1 (no)
WO (1) WO1994020131A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69632062T2 (de) 1995-11-02 2004-11-18 Schering Corp. Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US7208167B2 (en) 2000-08-07 2007-04-24 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis C with thymosin and peptide combination therapy
WO2002011754A1 (en) * 2000-08-07 2002-02-14 Sciclone Pharmaceuticals, Inc. Treatment of hepatitis c with thymosin and pegylated interferon
DK1613340T3 (da) 2003-03-28 2010-08-30 Sciclone Pharmaceuticals Inc Behandling af aspergillus-infektioner med thymosin alfa 1
RS52377B (sr) * 2006-05-02 2012-12-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Primena timozina 1, samog ili u kombinaciji sa ptx3 ili ganciklovirom, za lečenje infekcije citomegalovirusom
ES2599979T3 (es) * 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1216056B (it) * 1988-03-11 1990-02-22 Sclavo Spa Composizioni farmaceutiche contenenti timosina alfa 1.
TW224053B (no) * 1991-09-13 1994-05-21 Paul B Chretien

Also Published As

Publication number Publication date
CN1072961C (zh) 2001-10-17
KR960700741A (ko) 1996-02-24
CA2157479A1 (en) 1994-09-15
CN1092322A (zh) 1994-09-21
ATE204760T1 (de) 2001-09-15
DE69428112T2 (de) 2002-03-21
SG64894A1 (en) 1999-05-25
CA2157479C (en) 2000-08-08
MY121198A (en) 2006-01-28
KR100306024B1 (ko) 2001-11-30
DK0687181T3 (da) 2001-10-01
GR3037021T3 (en) 2002-01-31
NO953473L (no) 1995-09-04
FI954127L (fi) 1995-09-04
DE69428112D1 (de) 2001-10-04
ES2162862T3 (es) 2002-01-16
EP0687181B1 (en) 2001-08-29
AU683248B2 (en) 1997-11-06
WO1994020131A1 (en) 1994-09-15
JPH06279309A (ja) 1994-10-04
PT687181E (pt) 2002-01-30
FI954127A7 (fi) 1995-09-04
AU6275994A (en) 1994-09-26
NO320877B1 (no) 2006-02-06
EP0687181A1 (en) 1995-12-20
FI954127A0 (fi) 1995-09-04

Similar Documents

Publication Publication Date Title
DK0603305T3 (da) Anvendelse af et thymosin til behandling af hepatitis C
ATE262920T1 (de) Kontinuierliche, niedrigdosierte zytokine- infusionstherapie
EA199800674A1 (ru) Способ повторного лечения больных гепатитом с
DE69636734D1 (de) Nucleoside mit anti-hepatitis b virus wirksamkeit
EA200201263A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
IE45753L (en) Combating virus infections
AU3216695A (en) Lipid analogs for treating viral infections
ES541103A0 (es) Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales
DE60237721D1 (de) Kombinationstherapie mit omega-interferon zur behandlung von hepatitis c virus oder gelbfieber virus infektionen
NO953473D0 (no) Fremgangsmåte for behandling av hepatitt C i individer som er ikke-respondere overfor interferonbehandling
ATE76579T1 (de) Interferon-zusammensetzungen.
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
RU98109203A (ru) Способ лечения вирусного гепатита b у детей
GR3024236T3 (en) Use of leukoregulin for the treatment of animals infected with an envelope-virus
DE60121449D1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
BR112022006913A2 (pt) Métodos para tratar infecções virais de hepatite delta
RU2003125593A (ru) Способ лечения острого вирусного гепатита в
ECSP982492A (es) Terapia de interferones polietilenglicol, modificados
MY101495A (en) Treatment of diseases caused by viruses
MXPA05010173A (es) Metodo de desensibilizacion con virus anti-cancer.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees